Ohsu Knight Cancer Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.ohsu.edu/knight-cancer-institute

Clinical Trials

Evaluating the Human Papillomavirus Self-Collection Experience in Individuals Who Have Experienced Sexual Trauma

Completed

Conditions: Human Papillomavirus Infection
Cervical Carcinoma

Interventions: Procedure: HPV Self-Collection
Other: Interview
Other: Survey Administration

First Posted Date: 2022-07-14

Last Posted Date: 2023-06-27

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 16

Registration Number: NCT05458869

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

The Use of "Smart" Body-Weight Scales for Weight and Nutritional Monitoring in Patients with Head and Neck Cancer Undergoing Radiation Therapy

Not Applicable

Terminated

Conditions: Head and Neck Squamous Cell Carcinoma
Malignant Head and Neck Neoplasm

Interventions: Other: Medical Device Qardio® smart scale Usage and Evaluation
Other: Questionnaire Administration

First Posted Date: 2022-07-14

Last Posted Date: 2025-01-24

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 2

Registration Number: NCT05457478

Locations: 🇺🇸
Mid-Atlantic Permanente Medical Group, Rockville, Maryland, United States
🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatment of Chronic Pancreatitis and Benign Pancreatic Tumors

Phase 1

Not yet recruiting

Conditions: Chronic Pancreatitis
Recurrent Acute Pancreatitis
Benign Pancreatic Neoplasm

Interventions: Procedure: Pancreatectomy
Other: Quality-of-Life Assessment
Other: Treatment Planning

First Posted Date: 2022-07-12

Last Posted Date: 2025-02-07

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 12

Registration Number: NCT05453851

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Improving Decision-Making Encounters in Lung Cancer Using a Low-Literacy Conversation Tool

Not Applicable

Recruiting

Conditions: Lung Carcinoma

Interventions: Other: Best Practice
Other: Health Promotion and Education
Other: Questionnaire Administration

First Posted Date: 2022-06-07

Last Posted Date: 2025-04-09

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 300

Registration Number: NCT05407168

Locations: 🇺🇸
Hillsboro Medical Center, Hillsboro, Oregon, United States
🇺🇸
Adventist Health Portland, Portland, Oregon, United States
🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

and more 1 locations

Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia

Phase 1

Suspended

Conditions: Acute Myeloid Leukemia
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions: Drug: Decitabine and Cedazuridine
Drug: Entrectinib
Other: Laboratory Biomarker Analysis

First Posted Date: 2022-05-31

Last Posted Date: 2025-06-15

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 12

Registration Number: NCT05396859

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer

Early Phase 1

Withdrawn

Conditions: Advanced Fallopian Tube Carcinoma
Advanced Ovarian Carcinoma
Advanced Primary Peritoneal Carcinoma
Anatomic Stage IV Breast Cancer AJCC v8
Metastatic Triple-Negative Breast Carcinoma
Stage III Fallopian Tube Cancer AJCC v8
Stage III Ovarian Cancer AJCC v8
Stage III Primary Peritoneal Cancer AJCC v8
Stage IV Fallopian Tube Cancer AJCC v8
Stage IV Ovarian Cancer AJCC v8

Interventions: Drug: Wee1 Inhibitor ZN-c3

First Posted Date: 2022-05-10

Last Posted Date: 2023-05-06

Lead Sponsor: OHSU Knight Cancer Institute

Registration Number: NCT05368506

Feasibility of OmnEcoil System for Integrated Endorectal MRI and Transrectal MRI-Targeted Biopsy of the Prostate

Not Applicable

Suspended

Conditions: Prostate Carcinoma

Interventions: Device: Biopsy
Procedure: Endorectal Magnetic Resonance Imaging

First Posted Date: 2022-05-05

Last Posted Date: 2025-04-10

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 45

Registration Number: NCT05362032

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma

Phase 2

Withdrawn

Conditions: BCLC Stage B Hepatocellular Carcinoma
Unresectable Hepatocellular Carcinoma
Recurrent Hepatocellular Carcinoma
Locally Advanced Hepatocellular Carcinoma
BCLC Stage C Hepatocellular Carcinoma

Interventions: Biological: Atezolizumab
Procedure: Biopsy
Drug: Cabozantinib S-malate
Radiation: Yttrium Y 90 Glass Microspheres

First Posted Date: 2022-04-14

Last Posted Date: 2022-12-14

Lead Sponsor: OHSU Knight Cancer Institute

Registration Number: NCT05327738

At-Home Dermoscopy Artificial Intelligence

Not Applicable

Terminated

Conditions: Malignant Skin Neoplasm

Interventions: Other: Dermoscopy
Other: Digital Photography
Procedure: Self-Skin Examination
Device: Skin Examination with Sklip
Procedure: Skin Examination
Other: Survey Administration

First Posted Date: 2022-04-11

Last Posted Date: 2025-01-14

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 1

Registration Number: NCT05321784

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

SMMART Adaptive Clinical Treatment (ACT) Trial

Early Phase 1

Withdrawn

Conditions: Advanced Breast Carcinoma
Anatomic Stage IV Breast Cancer AJCC v8
Stage II Pancreatic Cancer AJCC v8
Stage III Ovarian Cancer AJCC v8
Advanced Prostate Carcinoma
Recurrent Adult Soft Tissue Sarcoma
Recurrent Breast Carcinoma
Stage IV Ovarian Cancer AJCC v8
Advanced Malignant Solid Neoplasm
Advanced Ovarian Carcinoma

Interventions: Drug: Alectinib
Drug: Alpelisib
Drug: Anastrozole
Biological: Atezolizumab
Biological: Bevacizumab
Procedure: Biopsy
Procedure: Biospecimen Collection
Drug: Capecitabine
Drug: Carboplatin
Drug: Cobimetinib
Drug: Entrectinib
Drug: Eribulin
Drug: Fulvestrant
Biological: Hyaluronidase-zzxf/Pertuzumab/Trastuzumab
Drug: Irinotecan
Drug: Letrozole
Drug: Nab-paclitaxel
Drug: Niraparib
Drug: Olaparib
Drug: Paclitaxel
Drug: Palbociclib
Biological: Pertuzumab
Other: Quality-of-Life Assessment
Biological: Trastuzumab
Biological: Trastuzumab Emtansine
Drug: Vemurafenib
Drug: Vinorelbine
Drug: Vismodegib

First Posted Date: 2022-02-14

Last Posted Date: 2024-01-23

Lead Sponsor: OHSU Knight Cancer Institute

Registration Number: NCT05238831

AI-Powered Research

Premium Access

Ohsu Knight Cancer Institute

Evaluating the Human Papillomavirus Self-Collection Experience in Individuals Who Have Experienced Sexual Trauma

The Use of "Smart" Body-Weight Scales for Weight and Nutritional Monitoring in Patients with Head and Neck Cancer Undergoing Radiation Therapy

A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatment of Chronic Pancreatitis and Benign Pancreatic Tumors

Improving Decision-Making Encounters in Lung Cancer Using a Low-Literacy Conversation Tool

Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia

ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer

Feasibility of OmnEcoil System for Integrated Endorectal MRI and Transrectal MRI-Targeted Biopsy of the Prostate

Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma

At-Home Dermoscopy Artificial Intelligence

SMMART Adaptive Clinical Treatment (ACT) Trial